Back to mobile site

Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

July 12, 2018 7:10 AM EDT Send to a Friend
Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login